# Alan Sandler

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/alan-sandler/

## Facts

| Field | Value |
| --- | --- |
| Citations | 43,717 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 55 |
| i10-index | 115 |
| Last Known Institution | Alector (United States) |
| OpenAlex ID | https://openalex.org/A5078389632 |
| ORCID iD | https://orcid.org/0009-0004-5397-5247 |
| Works | 218 |

## Researcher papers

- [Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer](https://scholariq.org/papers/paclitaxel-carboplatin-alone-or-with-bevacizumab-for-non-small-cell-lung-cancer/)
- [Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial](https://scholariq.org/papers/atezolizumab-versus-docetaxel-in-patients-with-previously-treated-non-small-cell/)
- [Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC](https://scholariq.org/papers/atezolizumab-for-first-line-treatment-of-metastatic-nonsquamous-nsclc/)
- [First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer](https://scholariq.org/papers/first-line-atezolizumab-plus-chemotherapy-in-extensive-stage-small-cell-lung/)
- [Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial](https://scholariq.org/papers/atezolizumab-versus-docetaxel-for-patients-with-previously-treated-non-small/)
- [Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer](https://scholariq.org/papers/efficacy-of-gefitinib-an-inhibitor-of-the-epidermal-growth-factor-receptor/)
- [Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC](https://scholariq.org/papers/atezolizumab-for-first-line-treatment-of-pd-l1-selected-patients-with-nsclc/)
- [TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/tribute-a-phase-iii-trial-of-erlotinib-hydrochloride-osi-774-combined-with/)
- [Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial](https://scholariq.org/papers/atezolizumab-in-combination-with-carboplatin-and-nab-paclitaxel-in-advanced/)
- [Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1–Selected Advanced Non–Small-Cell Lung Cancer (BIRCH)](https://scholariq.org/papers/phase-ii-trial-of-atezolizumab-as-first-line-or-subsequent-therapy-for-patients/)
- [Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)](https://scholariq.org/papers/differential-regulation-of-pd-l1-expression-by-immune-and-tumor-cells-in-nsclc/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

## Researcher university

- [Alector (United States)](https://scholariq.org/institutions/alector-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.